Patient-Derived Health State Utilities for Gastroesophageal Reflux Disease
Authors:
- Nighat UllahNUNighat Ullah
- Trevor HastieTHTrevor Hastie
- George TriadafilopoulosGTGeorge Triadafilopoulos
- Mary GoldsteinMGMary Goldstein
- 1 March 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 100 (3) , 524-533
Abstract
Gastroesophageal reflux disease is a chronic disease that adversely affects health-related quality of life. The purpose of this study was to derive health state utilities for patients with chronic heartburn symptoms. We used a custom-designed computer program in order to elicit utilities with the time-tradeoff and standard-gamble techniques. Patients with chronic (more than 6 months) symptoms of gastroesophageal reflux disease entered the study. Two interviews were performed in random sequence either initially on medications for heartburn that adequately controlled symptoms, or off of medications for 1 wk while the patient was symptomatic. We also collected data using visual-analog scales, quality of life in reflux and dyspepsia (QOLRAD), and Gastrointestinal Symptom Rating Scale (GSRS) scores. We invited 222 patients to participate; 158 (71%) patients (129 men, 29 women) completed the study. Barrett's esophagus was present in 40 (25%), erosive disease in 17 (11%), and 118 (74%) had comorbid conditions. The mean (+/-SD) utility ratings were 0.94 +/- 0.09 on medical therapy and 0.90 +/- 0.12 off medications for patients with reflux alone using time tradeoff (p= 0.004), and 0.94 +/- 8.0 both on and off of antireflux medications with standard-gamble assessment (p= 0.96). Mean time-tradeoff scores were also significantly lower off of medications for patients with other comorbid conditions (p= 0.002). There was no significant difference between mean utility scores for patients with or without Barrett's esophagus or erosive disease. Gastroesophageal reflux disease adversely affects health-related quality of life. Time-tradeoff utility for patients with reflux disease is substantially higher when patients are on medication than off medications.Keywords
This publication has 28 references indexed in Scilit:
- Rabeprazole Improves Health-Related Quality of Life in Patients with Erosive Gastroesophageal Reflux DiseaseDigestive Diseases and Sciences, 2002
- What Should Be Reported in a Methods Section on Utility Assessment?Medical Decision Making, 2001
- The Impact of Gastroesophageal Reflux Disease on Health-related Quality of LifeThe American Journal of Medicine, 1998
- The Effect of Search Procedures on Utility ElicitationsMedical Decision Making, 1998
- Dollars May Not Buy as Many QALYs as We Think:Medical Decision Making, 1997
- The importance of patient preferences for comorbidities in cost-effectiveness analysesJournal of Health Economics, 1997
- Automated utility assessment of global healthQuality of Life Research, 1996
- Prevalence of Symptoms Suggestive of Gastroesophageal Reflux Disease in an Adult PopulationAnnals of Medicine, 1995
- Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes StudyJAMA, 1989
- Symptomatic gastroesophageal reflux: Incidence and precipitating factorsDigestive Diseases and Sciences, 1976